Objective To establish and validate a nomogram for overall survival(OS) of patients after hepatectomy for hepatocellular carcinoma(HCC). Methods A retrospective analysis was performed for the clinical data of 1013 patients who underwent hepatectomy for HCC in The Affiliated Tumor Hospital of Guangxi Medical University from February 2004 to October 2013. These patients were randomly divided into training cohort with 710 patients and validation cohort with 303 patients. For the training cohort,the Cox proportional hazards model was used to determine independent risk factors and a nomogram was established to predict 1-,3-,and 5-year survival rates. The performance of this nomogram was evaluated by internal verification within the training cohort and external verification of the validation cohort,as well as C-index,receiver operating characteristic(ROC) curve,and calibration curve. The independent samples t-test was used for comparison of continuous variables between groups,and the chi-square test or the Fisher's exact test was used for comparison of categorical variables between groups. The Cox proportional hazards model was used for univariate and multivariate analyses. Results The 1-,3-,and 5-year OS rates in the training cohort were 0. 72,0. 48,and 0. 34,respectively,and those in the validation cohort were 0. 66,0. 45,0. 32,respectively. The univariate and multivariate analyses showed that age,number of tumors,tumor diameter,tumor capsule,vascular invasion,microsatellite lesion,aspartate aminotransferase(AST),and alpha-fetoprotein(AFP) were the influencing factors for OS in patients after hepatectomy for HCC(all P < 0. 05),and such factors were used to establish a nomogram model. In the training cohort,the C-index for predicting OS was 0. 748(95% confidence interval [CI]: 0. 712-0. 784); the calibration curve of 1-,3-,and 5-year survival rates showed that the predicted value of the nomogram was in good consistency with the actual values observed; this nomogram model had an area under the ROC curve of 0. 81(95% CI: 0. 76-0. 87),0. 82(95% CI: 0. 77-0. 88),and 0. 79(95% CI: 0. 71-0. 88),respectively,in predicting the 1-,3-,and 5-year survival rates. In the validation cohort,the C-index was 0. 712(95% CI: 0. 685-0. 739); the calibration curve of 1-,3-,and 5-year survival rates showed that the predicted value of the nomogram was in good consistency with the actual values observed; this nomogram model had an area under the ROC curve of 0. 75(95% CI: 0. 71-0. 79),0. 77(95%CI: 0. 73-0. 81),and 0. 74(95% CI: 0. 68-0. 80),respectively,in predicting the 1-,3-,and 5-year survival rates. Conclusion The nomogram established in this study can effectively predict OS in patients after hepatectomy for HCC.
[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.
|
[2] TABRIZIAN P,JIBARA G,SHRAGER B,et al. Recurrence of hepatocellular cancer after resection[J]. Ann Surg,2015,261(5):947-955.
|
[3] POON R,FAN S,LO C,et al. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function-Implications for a strategy of salvage transplantation[J]. Ann Surg,2002,235(3):373-382.
|
[4] LIAO R,FU YP,WANG T,et al. Metavir and FIB-4 scores are associated with patient prognosis after curative hepatectomy in hepatitis B virus-related hepatocellular carcinoma:A retrospective cohort study at two centers in China[J]. Oncotarget,2017,8(1):1774-1787.
|
[5] XIAO Z,YAN Y,ZHOU Q,et al. Development and external validation of prognostic nomograms in hepatocellular carcinoma patients:A population based study[J]. Cancer Manag Res,2019,11:2691-2708.
|
[6] PANG Q,ZHOU L,QU K,et al. Validation of inflammationbased prognostic models in patients with hepatitis B-associated hepatocellular carcinoma:A retrospective observational study[J]. Eur J Gastroenterol Hepatol,2018,30(1):60-70.
|
[7] CAI BB,SHI KQ,LI P,et al. A nomogram integrating hepatic reserve and tumor characteristics for hepatocellular carcinoma following curative liver resection[J]. Clin Chim Acta,2018,485:187-194.
|
[8] YU C,ZHANG Y. Development and validation of a prognostic nomogram for early-onset colon cancer[J]. Biosci Rep,2019,39(6). pii:BSR20181781.
|
[9] DENG W,ZHANG W,YANG J,et al. Nomogram to predict overall survival for thoracic esophageal squamous cell carcinoma patients after radical esophagectomy[J]. Ann Surg Oncol,2019,26(9):2890-2898.
|
[10] SHI HT,JIANG YQ,CAO HG,et al. Nomogram based on systemic immune-inflammation index to predict overall survival in gastric cancer patients[J]. Dis Markers,2018,2018:1787424.
|
[11] MAI RY,YE JZ,WANG YY,et al. Value of albumin-bilirubin score combined with aspartate aminotransferase-to-platelet ratio index in predicting the development of posthepatectomy liver failure in patients with HBV-related hepatocellular carcinoma[J]. J Clin Hepatol,2018,34(2):292-297.(in Chinese)麦荣云,叶甲舟,王言焱,等. ALBI联合APRI对HBV相关肝细胞癌肝切除术后肝衰竭发生的预测价值[J].临床肝胆病杂志,2018,34(2):292-297.
|
[12] CHEN W,ZHENG R,BAADE PD,et al. Cancer statistics in China,2015[J]. CA Cancer J Clin,2016,66(2):115-132.
|
[13] SHEN J,HE L,LI C,et al. Prognostic nomograms for patients with resectable hepatocelluar carcinoma incorporating systemic inflammation and tumor characteristics[J]. Oncotarget,2016,7(49):80783-80793.
|
[14] McGLYNN KA,PETRICK JL,LONDON WT. Global epidemiology of hepatocellular carcinoma[J]. Clin Liver Dis,2015,19(2):223-238.
|
[15] HSU CY,LIU PH,HSIA CY,et al. Nomogram of the Barcelona Clinic Liver Cancer system for individual prognostic prediction in hepatocellular carcinoma[J]. Liver Int,2016,36(10):1498-1506.
|
[16] ZHANG XP,CHEN ZH,ZHOU TF,et al. A nomogram to predict early postoperative recurrence of hepatocellular carcinoma with portal vein tumour thrombus after R0 liver resection:A large-scale,multicenter study[J]. Eur J Surg Oncol,2019,45(9):1644-1651.
|
[17] WANG Y,SUN K,SHEN J,et al. Novel prognostic nomograms based on inflammation-related markers for patients with hepatocellular carcinoma underwent hepatectomy[J].Cancer Res Treat,2019.[Epub ahead of print]
|
[18] CILLO U,VITALE A,GRIGOLETTO F,et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system[J]. J Hepatol,2006,44(4):723-731.
|
[19] GUGLIELMI A,RUZZENENTE A,PACHERA S,et al. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response[J]. Am J Gastroenterol,2008,103(3):597-604.
|
[20] GRIECO A,POMPILI M,CAMINITI G,et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy:Comparison of Okuda,CLIP,and BCLC staging systems in a single Italian centre[J]. Gut,2005,54(3):411-418.
|
[21] LIAO R,PENG C,LI M,et al. Comparison and validation of the prognostic value of preoperative systemic immune cells in hepatocellular carcinoma after curative hepatectomy[J].Cancer Med,2018,7(4):1170-1182.
|
[22] SHIM JH,JUN MJ,HAN S,et al. Prognostic nomograms for prediction of recurrence and survival after curative liver resection for hepatocellular carcinoma[J]. Ann Surg,2015,261(5):939-946.
|